{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:52:00Z","timestamp":1780642320022,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.vaccine.2009.02.079","type":"journal-article","created":{"date-parts":[[2009,3,10]],"date-time":"2009-03-10T09:14:50Z","timestamp":1236676490000},"page":"2884-2890","source":"Crossref","is-referenced-by-count":46,"title":["Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection"],"prefix":"10.1016","volume":"27","author":[{"given":"Yasuyuki","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanitha S.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia E.Z.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bertholet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"June (11)","key":"10.1016\/j.vaccine.2009.02.079_bib1","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","volume":"174","author":"Basu","year":"2005","journal-title":"J Immunol"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2009.02.079_bib2","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","article-title":"Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis","volume":"165","author":"Stager","year":"2000","journal-title":"J Immunol"},{"issue":"October (1\u20132)","key":"10.1016\/j.vaccine.2009.02.079_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections","volume":"20","author":"Ghosh","year":"2001","journal-title":"Vaccine"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2009.02.079_bib4","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/IAI.63.5.2062-2069.1995","article-title":"A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice","volume":"63","author":"Wilson","year":"1995","journal-title":"Infect Immun"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2009.02.079_bib5","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1086\/430348","article-title":"A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis","volume":"191","author":"Tewary","year":"2005","journal-title":"J Infect Dis"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2009.02.079_bib6","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/IAI.73.2.812-819.2005","article-title":"Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis","volume":"73","author":"Aguilar-Be","year":"2005","journal-title":"Infect Immun"},{"issue":"March (12)","key":"10.1016\/j.vaccine.2009.02.079_bib7","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.vaccine.2005.11.011","article-title":"Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis","volume":"24","author":"Rafati","year":"2006","journal-title":"Vaccine"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2009.02.079_bib8","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1128\/IAI.66.7.3279-3289.1998","article-title":"Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family","volume":"66","author":"Webb","year":"1998","journal-title":"Infect Immun"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2009.02.079_bib9","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/IAI.69.6.4103-4108.2001","article-title":"Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease","volume":"69","author":"Campos-Neto","year":"2001","journal-title":"Infect Immun"},{"issue":"October (42)","key":"10.1016\/j.vaccine.2009.02.079_bib10","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1016\/j.vaccine.2007.08.001","article-title":"Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant","volume":"25","author":"Goto","year":"2007","journal-title":"Vaccine"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2009.02.079_bib11","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/AAC.48.7.2409-2414.2004","article-title":"Cloning of S-adenosyl-l-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-resistant promastigotes","volume":"48","author":"Pourshafie","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2009.02.079_bib12","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.4049\/jimmunol.168.8.3992","article-title":"CD8+ T cells are required for primary immunity in C57BL\/6 mice following low-dose, intradermal challenge with Leishmania major","volume":"168","author":"Belkaid","year":"2002","journal-title":"J Immunol"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2009.02.079_bib13","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD(4+) T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect Immun"},{"issue":"May (1)","key":"10.1016\/j.vaccine.2009.02.079_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.exppara.2007.12.019","article-title":"Adhesion of MRP8\/14 to amastigotes in skin lesions of Leishmania major-infected mice","volume":"119","author":"Goto","year":"2008","journal-title":"Exp Parasitol"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2009.02.079_bib15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.4049\/jimmunol.165.2.969","article-title":"A natural model of Leishmania major infection reveals a prolonged \u201csilent\u201d phase of parasite amplification in the skin before the onset of lesion formation and immunity","volume":"165","author":"Belkaid","year":"2000","journal-title":"J Immunol"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2009.02.079_bib16","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.4049\/jimmunol.174.5.2934","article-title":"Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL\/6 mice","volume":"174","author":"Anderson","year":"2005","journal-title":"J Immunol"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2009.02.079_bib17","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1128\/IAI.72.10.5654-5661.2004","article-title":"Immunization with Leishmania major exogenous antigens protects susceptible BALB\/c mice against challenge infection with L. major","volume":"72","author":"Tonui","year":"2004","journal-title":"Infect Immun"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2009.02.079_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4269\/ajtmh.2007.76.579","article-title":"Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB\/c mice","volume":"76","author":"Tonui","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"June (19\u201320)","key":"10.1016\/j.vaccine.2009.02.079_bib19","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0264-410X(02)00189-5","article-title":"Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB\/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation","volume":"20","author":"Rafati","year":"2002","journal-title":"Vaccine"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2009.02.079_bib20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.4269\/ajtmh.2007.77.1060","article-title":"Protection of susceptible BALB\/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania","volume":"77","author":"Al-Wabel","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"May (22)","key":"10.1016\/j.vaccine.2009.02.079_bib21","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1016\/j.vaccine.2006.03.005","article-title":"Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani","volume":"24","author":"Gamboa-Leon","year":"2006","journal-title":"Vaccine"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2009.02.079_bib22","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","article-title":"Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis","volume":"70","author":"Coler","year":"2002","journal-title":"Infect Immun"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2009.02.079_bib23","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1084\/jem.170.6.2097","article-title":"Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis","volume":"170","author":"Titus","year":"1989","journal-title":"J Exp Med"},{"issue":"November (9)","key":"10.1016\/j.vaccine.2009.02.079_bib24","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.4049\/jimmunol.147.9.3149","article-title":"IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis","volume":"147","author":"Scott","year":"1991","journal-title":"J Immunol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2009.02.079_bib25","first-page":"157","article-title":"Intracellular destruction of Leishmania tropica by macrophages activated with macrophage activating factor\/interferon","volume":"55","author":"Titus","year":"1984","journal-title":"Clin Exp Immunol"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2009.02.079_bib26","first-page":"570","article-title":"Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis","volume":"69","author":"Liew","year":"1990","journal-title":"Immunology"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2009.02.079_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2009.02.079_bib28","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.4049\/jimmunol.145.12.4306","article-title":"Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide","volume":"145","author":"Liew","year":"1990","journal-title":"J Immunol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2009.02.079_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1084\/jem.171.1.115","article-title":"Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism","volume":"171","author":"Sadick","year":"1990","journal-title":"J Exp Med"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2009.02.079_bib30","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.4049\/jimmunol.150.11.5059","article-title":"Transfected Leishmania expressing biologically active IFN-gamma","volume":"150","author":"Tobin","year":"1993","journal-title":"J Immunol"},{"issue":"May (9)","key":"10.1016\/j.vaccine.2009.02.079_bib31","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.4049\/jimmunol.164.9.4819","article-title":"In BALB\/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease","volume":"164","author":"Himmelrich","year":"2000","journal-title":"J Immunol"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2009.02.079_bib32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.20041470","article-title":"A role for IgG immune complexes during infection with the intracellular pathogen Leishmania","volume":"201","author":"Miles","year":"2005","journal-title":"J Exp Med"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2009.02.079_bib33","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4049\/jimmunol.166.2.1141","article-title":"The role of IL-10 in promoting disease progression in leishmaniasis","volume":"166","author":"Kane","year":"2001","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09003399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09003399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T09:14:25Z","timestamp":1684919665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09003399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":33,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0264410X09003399"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.02.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}